FidoCure^® Veterinary Team Blog

Sir Oliver, an 8 year old French Bulldog with TCC, is surviving and thriving thanks to his targeted therapeutic treatment4.5 months from FidoCure™ enrollment, Sir Oliver's latest CT scan showed a 38% reduction in his bladder tumor.

After one year of FidoCure®targeted therapy, Missy showed no evidence of pulmonary metastatic disease.

 

It is clear that the utilization of targeted therapy has proven beneficial in improving patient quality of life, extending survival time with minimal disease progression, and having an overall positive impact on patient care.

After six months of FidoCure® enabled therapy, Adley showed no evidence of pulmonary mass recurrence.

 

A 11 yr old Golden with hemophagocytic histiocytic sarcoma, 38 months in remission. FidoCure® identified a rare tumor suppressor mutation and suggested additional therapy that may have helped target tumor cells.

After more than 20 months of FidoCure® enabled treatment, Lulu has remained free from further metaseses. There has been no evidence of disease recurrence or pulmonary metastasis. Lulu has maintained a positive quality of life while in treatment and achieved extended time with her pet owners.

Resilience is defined as the capacity to recover quickly from difficulties and toughness-- there are both physical and psychological resilience. Both have been severely tested these last few years with the pandemic, the current war, national divisions, etc. and have really affected veterinarians in the world at large.

An introduction from Chief Medical Officer, Dr. Gerry Post

Veterinary medicine is changing. I remember one of my first days in veterinary school looking at the class pictures that were hung in the hallways. I remember seeing the first woman in one of these class photos and noting that she was still practicing.

PIK3CA and KRAS mutations predict for response to everolimus therapy: now that’s RAD001 Morassa Mohseni, Ben Ho Park J Clin Invest. 2010;120(8):2655-2658. https://doi.org/10.1172/JCI44026.

Jeylan Aslan, Michael A. Shipstone and Louise M. Sullivan Vet Dermatol. 2021 May 25. doi: 10.1111/vde.12976

This case study reviews the use of olacitinib to treat cutaneous epitheliotropic T-cell lymphoma (CETL).